CytoSorbents Selected to Present on HemoDefend(TM) at the Military Health System Research Symposium

CytoSorbents Selected to Present on HemoDefend(TM) at the Military Health 
System Research Symposium 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/26/13 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company working to
save lives through blood purification, announced that it has been
selected to make a presentation of its HemoDefend(TM) blood
purification technology at the Military Health System Research
Symposium (MHSRS), the premier U.S. scientific meeting focused on
medical advances that address the unique medical needs of the
warfighter.  
HemoDefend(TM) is a novel blood purification technology designed to
reduce a broad range of dangerous contaminants, such as free
hemoglobin, antibodies, bioactive lipids, and cytokines, in
transfused blood products that can cause potentially deadly
transfusion reactions and adverse outcomes in patients receiving
packed red blood cells and platelets. It is based upon CytoSorbents'
highly biocompatible porous polymer bead technology platform and can
be implemented either as an in-line filter at the point of
transfusion, or in an innovative "Beads-in-a-Bag" configuration where
the polymer beads purify blood directly in the blood storage bag.  
"Blood is a life-saving therapy not only for our wounded warfighters,
but for millions of civilians each year. Nearly 85 million units of
packed red blood cells and 10 million platelet units are transfused
worldwide annually. But receiving blood is not without risk and can
sometimes lead to more harm than good," said Dr. Phillip Chan, CEO of
CytoSorbents. "By broadly reducing the contaminants in blood that can
cause transfusion reactions and bad outcomes, HemoDefend(TM)
represents one of the newest innovations in improving the quality and
safety of the blood supply." 
The MHSRS conference, which attracted more than 1,500 participants
last year, will be held at the Harbor Beach Marriott Hotel in Fort
Lauderdale, Florida, from August 12-15, 2013. Dr. Chan will present
the HemoDefend(TM) technology platform on Monday, August 12, 2013 at
3:40PM. CytoSorbents will also be showcasing its blood purification
technologies, including CytoSorb(R) and HemoDefend(TM), during the
conference in the exhibition hall. HemoDefend(TM) is under advanced
development and not yet approved for commercial sale. 
About MHSRS 
The MHSRS conference provides a collaborative environment for
military medical care providers and scientists from the US Department
of Defense (including all branches of the military), academia, and
industry, as well as those from allied countries, to discuss and
address the advancement of research and health care development in
areas of Combat Casualty Care, Military Operational Medicine,
Clinical and Rehabilitative Medicine, and Military Infectious Disease
Research Programs. (https://www.mhsrs.org).  
About CytoSorbents Corporation  
CytoSorbents is a critical care focused therapeutic device company
specializing in blood purification. CytoSorb(R), the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as sepsis,
burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective
treatments exist. The goal of CytoSorb(R) is to prevent or treat
multiple organ failure, the cause of nearly half of all deaths in the
intensive care unit, with little available to improve clinical
outcome. CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products under
development based upon this unique blood purification technology,
protected by 32 issued US patents and multiple applications pending,
including HemoDefend(TM), ContrastSorb, DrugSorb, and others.
Additional information is available for download on the Company's
website: http://www.cytosorbents.com 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at
http://www.sec.gov. 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
asheinwald@allianceadvisors.net 
Valter Pinto
(914) 669-0222 x201
valter@allianceadvisors.net 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378
jabraham@jqapartners.com 
 
 
Press spacebar to pause and continue. Press esc to stop.